We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approa... Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease. Show more
SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.Β (Nasdaq:Β ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02...
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.Β (Nasdaq:Β ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.Β (Nasdaq:Β ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.Β (Nasdaq:Β ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 8.69565217391 | 1.15 | 1.25 | 1.1 | 10104 | 1.1553217 | CS |
4 | 0.12 | 10.6194690265 | 1.13 | 1.2999 | 1.07 | 13560 | 1.2127833 | CS |
12 | -0.0101 | -0.801523688596 | 1.2601 | 1.34 | 1 | 9051 | 1.20721199 | CS |
26 | -0.1 | -7.40740740741 | 1.35 | 1.58 | 1 | 46038 | 1.32324482 | CS |
52 | -0.1 | -7.40740740741 | 1.35 | 1.75 | 1 | 31261 | 1.35072018 | CS |
156 | 0.17 | 15.7407407407 | 1.08 | 7.2 | 0.2599 | 365448 | 1.14975294 | CS |
260 | -1.05 | -45.652173913 | 2.3 | 7.2 | 0.2599 | 1232399 | 1.40792262 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions